Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A pre-specified meta-analysis of pooled, individual patient-level data from the DELIVER and DAPA-HF trials, testing dapagliflozin in patients with heart failure, demonstrates reductions in risk of cardiovascular-associated deaths and hospital admissions for heart failure, regardless of ejection fraction.
A large-scale population analysis quantifies the burden of mental illness and self-harm events in patients diagnosed with the most common adult cancers and highlights opportunities for advancing patient care.
A global analysis across 62 studies, of which 28 were meta-analyzed, reveals an increased risk of death by suicide in patients with cancer and underscores the need for comprehensive psycho-oncological therapy during clinical routine to improve the quality of life of patients.
Meta-analysis of cardiovascular secondary outcomes from the SURPASS program, testing efficacy of a new novel dual GIP/GLP-1 receptor agonist tirzepatide, demonstrates cardiovascular safety in patients with type 2 diabetes.